The partial response to CCL2/CCR2 targeting strategies highlights that other chemokines, cytokines and growth factors contribute to the process, or may compensate the absence of CCL2/CCR2, with differences depending on the stage and the type of tumor, that hence need to be carefully evaluated for the development of effective strategies. The gene discussed is CCL2; the disease is neoplasm.